Introduction
In healthy individuals, primary infection with human cytomegalovirus (HCMV) is followed by life-long persistence with viral latency in cells of the myeloid lineage. HCMV-specific CD8 ϩ T cells play an important role in controlling HCMV reactivation and preventing overt disease. Healthy HCMV carriers have large circulating populations of HCMV-specific CD8 ϩ T cells, many of which recognize defined peptides derived from the virus tegument protein pp65 1 or the major immediate early protein (IE72). 2 In a given virus carrier, the CD8 ϩ T-cell response against a given HCMV peptide is often dominated by relatively few individual clones that are greatly expanded and maintained in peripheral blood mononuclear cells (PBMCs) for long periods. 3 In immunosuppressed patients such as recipients of allogeneic stem cell (alloSC) transplants, uncontrolled HCMV reactivation frequently leads to HCMV disease and is a major cause of procedure-related morbidity and mortality. 4 In alloSC transplant recipients, reconstitution of HCMV-specific CD8 ϩ T-cell responses is associated with reduced incidence of HCMV disease. 5, 6 The mechanisms of CD8 ϩ T-cell reconstitution following alloSCT in humans are incompletely understood. Antigen-driven peripheral expansion of mature donor T cells transplanted within the allograft appears to predominate for initial CD8 ϩ T-cell reconstitution. 7 In addition, CD8 ϩ thymic emigrants identified by T-cell receptor (TCR) excision circle (TREC) analysis can be observed by 2 months after allogeneic SCT, 8 suggesting that there is production of naive T lymphocytes from donor-derived progenitor cells that have undergone TCR gene recombination in the thymus of the recipient. TREC analysis does not directly assess T-cell function, and it is unclear how soon following alloSCT a primary CD8 ϩ T-cell response can develop in the recipient. The T cells that participate in a primary response in the recipient following alloSCT may include preexisting naive T cells transferred from the donor in the allograft, T cells newly generated in the recipient from donor-derived progenitor cells (via thymic or nonthymic pathways), or recipient T cells that survived the preparative chemoradiotherapy regimen.
Some but not all studies have reported an association between donor HCMV-seropositive status and protection against HCMV disease. 4, 9 Transfer of immune cells within the allograft from HCMV-seropositive donors may provide cellular immunity to the recipient; in addition HCMV-specific CD8 ϩ T cells grown in vitro have been adoptively transferred into alloSC transplant recipients to restore immunity. 5 The spontaneous reconstitution of HCMVspecific CD8 ϩ T cells in recipients following alloSCT has been monitored with the use of peptide-major histocompatibility complex (MHC) class I tetramers. 6, 10, 11 In recipients of sibling allografts in which both the recipient and donor were HCMVseropositive before alloSCT, reconstitution of HCMV-specific CD8 ϩ T cells was rapid; early reconstitution of tetramer ϩ cells was not observed if either the donor or recipient was seronegative for HCMV. Tetramer staining does not identify whether the CD8 ϩ T cells originate from the donor or from recipient cells, and it does not distinguish the individual T-cell clones that comprise the tetramer ϩ population. Analysis of the reconstitution of HCMVspecific CD8 ϩ T cells at the clonal level provides an important model to address fundamental mechanisms of human antigenspecific CD8 ϩ T-cell reconstitution following alloSCT. We studied the origin and kinetics of reconstitution of individual virus-specific CD8 ϩ T-cell clones following alloSCT. Individual clones were distinguished by the hypervariable sequence of the T-cell receptor ␤ chain that is generated by the recombination of the V, D, and J gene segments during T-cell development. We derived multiple functional CD8 ϩ T-cell clones specific for defined peptides of HCMV pp65, HCMV IE72, or EBV EBNA3C from healthy allograft donors and from their corresponding recipients before and after alloSCT and sequenced the hypervariable region of the TCR ␤ chain. We used the TCR ␤ chain hypervariable sequence to design a complementary clonotype-specific oligonucleotide to quantify each individual virus-specific T-cell clones in PBMCs by molecular clonotype probing. For each biologic clone obtained from a transplant recipient, we also determined whether the clone was of recipient or donor origin by analysis of DNA for sex chromosome and/or informative single nucleotide polymorphisms (SNPs).
Patients, materials, and methods

Donor-recipient pairs
We studied alloSC transplant recipients and their donors who had either HLA-A02.01, HLA-B07.02, HLA-B08.01, HLA-B35, or HLA-B44.02 alleles, in whom the recipient and/or the donor were seropositive for HCMV and/or EBV (immunoglobulin G [IgG] enzyme-linked immunosorbent assay [ELISA] ; Public Health Laboratory Services, Addenbrooke's Hospital, Cambridge, United Kingdom). Ethical approval was obtained from the Addenbrookes NHS Hospital Trust institutional review board for this study. All recipients provided informed consent according to the Declaration of Helsinki (LREC 97/129). Details of donor-recipient pairs are summarized in Table 1 . We studied recipients 04 and 06 at 6 years after alloSCT; all other donor-recipient pairs were studied prospectively from the time of transplantation.
Transplantation protocols
Stem cell harvesting, administration of the total body irradiation/ cyclophosphamide preparative regimen, and prophylaxis against graftversus-host-disease (GVHD) were performed as previously described. 12 All alloSC transplant recipients received HCMV-negative irradiated blood products. Recipients received prophylaxis with oral or intravenous ganciclovir from day ϩ30 to day ϩ100. HCMV infection was monitored by weekly plasma samples tested for HCMV DNA by polymerase chain reaction (PCR), and HCMV serology (Public Health Laboratory Services, Addenbrooke's Hospital) until cessation of immunosuppression. Recipients who developed HCMV DNAemia or HCMV disease were treated with intravenous immunoglobulin 1 mg/kg on days ϩ1 and ϩ7 and intravenous ganciclovir 5 mg/kg twice daily for at least 2 weeks. To prevent GVHD, sibling allograft recipients received cyclosporin (commencing on day Ϫ1) and short-course methotrexate, and HLA-matched unrelated donor allograft recipients received cyclosporin and intravenous alemtuzumab (Campath-1H) monoclonal antibody from day Ϫ5 through day ϩ4. Cyclosporin was generally continued for at least 6 months.
Viral peptides
Peptides used were HCMV pp65 495 CSA 0-4 mo, died at 6 mo AML indicates acute myeloid leukemia; PBSC, peripheral blood stem cell; ND, not done; CSA, cyclosporin A; PD, prednisolone; B-ALL, B-acute lymphoblastic leukemia; CML, chronic myeloid leukemia; AZ, azathioprine; BM, bone marrow; TCD-MUD, T-cell-depleted matched-unrelated donor; RAEB-T, refractory anemia with excess blasts in transformation.
*Recipient serology performed on a sample taken before transplantation. †HCMV DNAemia was monitored by weekly plasma samples tested by PCR, until cessation of immunosuppression. ‡All episodes of HCMV infection resolved with ganciclovir treatment. §Patient was treated palliatively from 4 months onward.
University, Berlin, Germany). Peptides were dissolved in RPMI at a final concentration of 40 g/mL.
Generation of biologic T-cell clones and determination of TCR ␤ chain hypervariable sequence
Blood samples were taken from donors and from recipients before and after transplantation. PBMCs were prepared by gradient centrifugation (Lymphoprep; Nyegaard, Oslo, Norway). Prior to limiting dilution (LDA) culture, CD16 ϩ natural killer (NK) cells were depleted by using anti-CD16 monoclonal IgM antibody (Leu-11b; Becton Dickinson, Oxford, United Kingdom) and complement. For healthy donors, CD4 ϩ cells were also depleted with anti-CD4-conjugated magnetically activated cell sorter (MACS) microbeads according to the manufacturers' instructions (Miltenyl Biotech, Bisley, United Kingdom). CD16-depleted responder cells were stimulated with viral peptide in LDA culture by using peptide-labeled irradiated autologous PBMCs in RPMI supplemented with 10% human AB serum and human recombinant interleukin 2 (IL-2; final concentration 5 IU/mL) as previously described. 14 The cultures were incubated at 37°C with 5% CO 2 , were re-fed every 5 days, and on day 14 were assayed for peptide-specific cytotoxicity in split-well analysis against 51 chromium-radiolabeled autologous or MHCmismatched lymphoblastoid B-cell lines pulsed with peptide or unpulsed, as previously described. 1 LDA wells that showed high levels of MHCrestricted peptide-specific lysis were used to generate independent CD8 ϩ T-cell clones by formal single-cell cloning by subculture at 0.5 cells/well, followed by restimulation with mitogen phytohemagglutinin (PHA) and irradiated allogeneic PBMCs from unrelated healthy subjects, as previously described. 3 After 2 to 3 weeks, clones were retested for peptide-specific lysis and selected on the basis of strong killing (Ͼ 30% specific lysis) against the peptide-pulsed target and minimal killing against the unpulsed target (Ͻ 10% specific lysis). After a minimum of 10 days from last addition of feeder cells, RNA from each clone was extracted, reverse transcribed, and PCR amplified by using a panel of 36 TCR V␤ familyspecific primers together with the corresponding C-region specific primer (synthesized by Genosys Biotechnologies, Cambridge, United Kingdom) as previously described. 3 The amplified PCR product was purified (Qiagen, West Sussex, United Kingdom) and sequenced by automated DNA sequencing (Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom).
Quantitation of TCR clonotypes
We designed 12mer to 21mer oligonucleotide probes complementary to the hypervariable nucleotide sequence of TCR ␤ chains of individual CD8 ϩ T-cell clones (Table 2) ; such probes are highly specific for individual CD8 ϩ T-cell clonotypes. 15 Cellular mRNA from donor PBMCs, donor allograft, or recipient PBMCs was reverse transcribed into cDNA and amplified by using the appropriate TCR V␤ region and C␤ region PCR primers. All recipient peptide-specific CD8 ϩ T-cell clones were obtained following alloSCT except for clone 5.1 from recipient 05, which was obtained prior to alloSCT. Donor clones 1.1, 2.1, 3.1a, and 3.1b had identical TCR V␤ chain nucleotide sequences to after alloSC transplant recipient clones 1.3, 2.2, 3.2a, and 3.2b, respectively. No virus-specific donor clones were obtained from donor 05 (HCMV seronegative) or donor 09 (fresh PBMCs not obtainable). Brackets indicate from which donor the clones were derived.
BLOOD, 1 NOVEMBER 2003 ⅐ VOLUME 102, NUMBER 9 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From A positive control sample from the original defined CD8 ϩ T-cell clone and a negative control sample from pooled PBMCs of 4 HCMV-seronegative donors were amplified simultaneously by using the same primers. Each PCR product was blotted onto a nylon filter and incubated overnight with ␥ 32 P end-labeled clonotypic probe in hybridization buffer. After washing, the amount of probe that had bound to each sample on the filter was quantitated by using an Instant Imager (Beckman, Hialeah, FL). The filter was stripped, washed, and then rehybridized with a radiolabeled TCR C␤ constant region probe that detects all amplified TCR sequences. In each sample studied, we calculated the relative abundance of the clonotype sequence as a proportion of all TCR sequences of the same V␤ family as follows: percentage of relative abundance of clonotype sequence ϭ (cpm clonotypic probe/cpm TCR constant probe) test sample/(cpm clonotypic probe/cpm TCR constant probe) positive control clone ϫ 100.
We used TCR V␤-specific monoclonal antibodies to quantify by flow cytometry the proportion of CD8 ϩ T cells in PBMCs that expressed the corresponding TCR V␤ chain. The clone size per 10 6 CD8 ϩ T cells could then be estimated, as previously described. 16 In selected samples from donor-recipient pair 01, we also used seminested PCR to increased sensitivity of detection of clonotype sequences. Initial PCR amplification used the V␤-and C␤-specific primers, followed by further PCR amplification using the relevant internal TCR J␤-specific primer. Clonotype probing was then performed as described in "Quantitation of TCR clonotypes," and rehybridization was performed using the relevant TCR J␤ chain region-specific probe as a control to detect all V␤-J␤ amplified sequences. The relative abundance of the clonotype sequence as a proportion of all TCR sequences within the same V␤-J␤ family was calculated.
Determination of the origin (donor versus recipient) of peptide-specific CD8 ؉ T-cell clones
DNA from donor PBMCs and recipient pretransplantation PBMCs (or buccal scrape) was analyzed to identify an informative DNA polymorphism; peptide-specific CD8 ϩ T-cell clones obtained from the recipient after alloSCT were then analyzed for the appropriate polymorphism. In cases of donor-recipient sex mismatch, PCR amplification using primers at the amelogenin locus was performed by Molecular Genetics Laboratory, Addenbrooke's Hospital as previously described. 17 Otherwise, analysis of SNPs was undertaken. Analysis of methyl-tetra-hydrofolate-reductase variant (MTHFRC677T), tumor necrosis factor-␣, and the apolipoprotein B (XbaI, EcoRI, and MspI) SNPs were performed by the Department of Haematology, Addenbrooke's Hospital, according to previously published methods. 18 HPA genotyping for human platelet antigen (HPA) 1, 2, 3, and 5 was performed using the PCR with sequence-specific priming (SSP) method described by Cavanagh et al 19 by the National Blood Service East Anglia Centre, Addenbrooke's Hospital.
Flow cytometry
Monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), TriColor (TC), or allo phycocyanin were specific for CD3, CD4, CD8, CD16, CD27, CD28, CD45RO, CD45RA, CD57, HLA-DR (TCS Biologicals, Burlingdale, CA) or V␤2, V␤14 (Immunotech, Marseilles, France), and V␤ 13.1 (Serotech, Oxford, United Kingdom). IgM-unconjugated monoclonal antibody against antichemokine receptor CCR7 (Pharmingen, San Diego, CA) was followed by biotin-conjugated anti-IgM (Pharmingen), and then stained with streptavidin Red 670 (Gibco BRL, Grand Island, NY). We used peptide-MHC class I tetramers that incorporated HCMV pp65 495-503 or pp65 [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] (kind gift of Dr J. Lipolis, NIH Core Tetramer Facility, Atlanta, GA) or HCMV IE72 [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] (kind gift of Florian Kern, Charitie, Humbolt University). Flow cytometry was performed on a fluorescence activated cell sorting (FACS) Calibur (Becton Dickinson) cytometer, and results were analyzed using WinMDI 2.7 software.
Results
All virus-specific CD8 ؉ T-cell clones identified in the recipient after alloSCT were of donor origin
For each virus-specific CD8 ؉ T-cell clone obtained from a recipient (Table 2) , we determined whether the clone was of recipient or donor origin by analysis of DNA polymorphisms. All HCMVspecific and EBV-specific CD8 ؉ T-cell clones were obtained from a contained DNA of donor origin (Table 3 ). An HCMV pp65 495-503 -specific CD8 ϩ T-cell clone (clone 5.1, Table 4 ) obtained from the recipient prior to alloSCT could not be detected by clonotype probing following transplantation at 6 sequential time points (range, 3-18 months), indicating that this recipient clone did not survive the preparative regimen. Using peptide stimulation, we generated multiple independent HCMV pp65-specific CD8 ϩ T-cell clones from 4 donorrecipient pairs 01 to 04 after alloSCT (Table 3) . Clones from recipients 01 to 03 had identical TCR ␤-chain nucleotide sequences to the peptide-specific CD8 ϩ T-cell clones obtained from the corresponding donor (clones 1.1, 2.1, 3.1a, and 3.1b, respectively). As we previously reported 3 in a given subject many of the independently derived clones specific for a defined peptide had an identical TCR ␤-chain sequence, for example, in donor 02, 3 of 3 independent clones had the same TCR ␤-chain sequence (clone 2.1). In recipient 03, 6 of 8 independent clones had an identical sequence (clone 3.2a), which was the same as that of 3 of 4 clones in donor 03 (clone 3.1a); similarly in the same recipient 2 of 8 clones (clone 3.2b) had an individual sequences to 1 of 4 clones in donor 03 (clone 3.1b). We designed clonotype probes specific to the hypervariable region of the TCR ␤ chain of donor clones (1.1, 1.2, 2.1, 3.1a, 4.1). It was not possible to use a probe for clone 3.1b because the probe underwent self-annealing with formation of a secondary structure. For clonotype probing, results are expressed as the percentage of clonotype sequence within all the TCR sequences of the same V␤ family. In each D ϩ /R ϩ pair, we detected donor clonotype within donor PBMCs (and in allograft harvest material in donor 01), and in the recipient PBMCs at all time points tested from 1 month to 6 years following alloSCT. Clonotype was undetectable in any PBMC samples obtained from recipients 02 and 03 prior to transplantation ( Figure 1A ; Table 4 ). Following alloSCT, corticosteroid therapy for GVHD was associated with a relative decline in HCMV-specific clonotype after alloSCT (Table 4 , recipient 01). In recipients 01 to 04 blood tests to detect HCMV DNAemia were performed weekly until cessation of immunosuppression and were consistently negative.
Recipient 10 underwent HCMV D ϩ /R ϩ HLA-matched unrelated donor alloSCT, and this recipient received in vivo alemtuzumab monoclonal antibody to deplete T cells. This recipient also received cyclosporin for 4 months after alloSCT, then cyclosporin was discontinued in an attempt to induce a graft-versus-leukemia response to combat leukemia relapse. Despite ongoing ganciclovir prophylaxis, this recipient became HCMV PCR positive on day ϩ46. HCMV viremia resolved after 2 weeks of ganciclovir therapy, then ganciclovir prophylaxis
. HCMV viremia recurred on day ϩ97 and again responded to antiviral therapy. Recipient 10 died of leukemia relapse at 6 months. In donor 10, we generated 2 different peptide-specific CD8 ϩ T-cell clones (pp65 495-503 -specific clone 10.1 and pp65 397-411 -specific clone 10.2). By clonotype probing, both clones were undetectable in recipient 10 prior to T-celldepleted alloSCT and at time points before and after viremia.
We also analyzed 2 EBV D ϩ /R ϩ pairs. An EBV EBNA3C 880-891 -specific CD8 ϩ T-cell clone from donor 07 (clone 7.2) was detected in recipient 07 at 4 time points from 2 to 30 months after alloSCT (Figure 2) . In recipient 09, at 1 year after alloSCT 2 independently derived EBV EBNA3C 880-891 -specific CD8 ϩ T-cell clones had identical TCR ␤-chain sequences (clone 9.1). We detected this clonotype in donor 09 PBMCs, in donor allograft material, and in the recipient at all time points tested from 4 to 30 months after alloSCT (Table 4) .
At late time points after cessation of immunosuppressive therapy, the functional peptide-specific cytotoxic T lymphocyte precursor (CTLp) frequencies determined by LDA in recipients 01 to 04 were similar to those observed in their respective donors (Table 5 ). In donor-recipient pair 01, in which the responses against 2 different HCMV peptides were studied, the higher relative frequency of pp65-specific CTLp compared with IE72-specific CTLp in the donor was also maintained in the recipient. The clone sizes per 10 6 CD8 ϩ T cells in PBMCs in donor 01 were 24 000 cells for the pp65-specific clone 1.1 and 12 000 cells for the IE72-specific clone 1.2; in recipient 01 at 5 months following alloSCT the clone sizes were 19 000 cells for the pp65-specific clone 1.1 and 4000 cells for the IE72-specific clone 1.2 and 1000 cells for the IE72 clone 1.4. To address the in vitro cloning efficiency in donor-recipient pairs 01 to 04, the frequency of pp65 tetramer ϩ CD8 ϩ T cells in PBMCs was determined by flow cytometry, and the ratio of the frequency of pp65 peptide-specific CTLp in LDA to the frequency of pp65 tetramer ϩ CD8 ϩ T cells was calculated (Table 5) . Within each D ϩ /R ϩ donor-recipient pair, the frequencies of pp65 tetramer ϩ CD8 ϩ T cells were similar, and the ratio of the CTLp frequency to the frequency of tetramer ϩ cells was also generally consistent. In both donors and recipients, the frequency of pp65-specific CTLp was generally only 3-fold lower than the frequency of pp65 tetramer ϩ CD8 ϩ T cells. The in vitro cloning efficiency was also assessed in recipient 05 (after alloSCT), and in donors 06 to 08 and 10. Results are shown in Table 5 . To determine whether the absence of detectable HCMV in the recipient influenced the reconstitution of HCMV-specific CD8 ϩ T cells, we analyzed 3 D ϩ /R Ϫ pairs (06-08). None of these 3 recipients had HCMV DNAemia on weekly blood samples, and none showed evidence of seroconversion following transplantation; in each case, anti-HCMV IgG antibody titers declined with 
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In donor 06, 2 different HCMV pp65 495-503 -specific CD8 ϩ T-cell clones were obtained (clones 6.1a and 6.1b). Neither of these clones was detectable in the recipient PBMC sample taken at 6 years after transplantation (Table 4 ). In donor PBMCs we found HCMV pp65 495-503 tetramer ϩ CD8 ϩ T cells (650 ϫ 10 4 /L tetramer ϩ CD8 ϩ CD3 ϩ T cells), but we were unable to detect any pp65 tetramer ϩ cells in the recipient PBMCs following alloSCT (Table  4) . Using LDA, we could not detect HCMV pp65 495-503 -specific CTLp in this recipient. The donor EBV was seronegative, and the recipient was EBV-seropositive; as an internal control we did detect a primary EBV-specific CD8 ϩ T-cell response in the recipient, both as functional EBNA3C 281-290 -specific CTLp in LDA, and EBNA3C 281-290 -specific clonotype 6.2 (which contained donor DNA) by clonotype probing was detectable in the recipient but not the donor (Table 4 ).
An immunodominant HCMV pp65 417-426 -specific clone 7.1 from donor 07 could not be detected in any of the recipient 07 PBMC samples taken at 2, 4, 9, and 24 months following alloSCT (Table 4) . We detected HCMV pp65 417-426 tetramer ϩ cells in both donor 07 PBMCs (0.4% of CD8 ϩ CD3 ϩ T cells were tetramer ϩ , total 200 ϫ 10 4 /L tetramer ϩ CD8 ϩ CD3 ϩ T cells) and within donor 07's mobilized peripheral blood stem cells (0.77% of CD8 ϩ CD3 ϩ For personal use only. on October 3, 2017. by guest www.bloodjournal.org From T cells were tetramer ϩ , total 300 ϫ 10 4 /L tetramer ϩ CD8 ϩ CD3 ϩ T cells), but not in recipient 07 PBMCs at 30 months after alloSCT ( Figure 2A ; Table 4 ). Of interest, this donor-recipient pair was D ϩ /R ϩ with respect to EBV; the donor EBV EBNA3C 880-889 -specific clone 8.2 obtained from the EBV-seropositive donor was readily detectable in the EBV-seropositive recipient at all time points after alloSCT ( Figure 2B ; Table 4 ).
In the third D ϩ /R Ϫ pair, a donor HCMV pp65 495-503 -specific CD8 ϩ T-cell clone (clone 8.2) was detected in donor 08 PBMCs (8.4%), and in recipient 08 at 2 months (5.5%), 3 months (6.5%), and 5 months (9.6%) after transplantation (positive control, 100%; negative control, 0.5%) ( Figure 2C ; Table 4 ). This recipient developed severe acute GVHD, was treated palliatively from 4 months onward, and died of leukemia relapse at 6 months. Weekly blood tests for HCMV DNA were consistently negative. We observed HCMV pp65 495-503 tetramer ϩ CD8 ϩ T cells in donor PBMCs (700 ϫ 10 4 /L) and in a recipient PBMC sample taken at 3 months (890 ϫ 10 4 /L). We analyzed EBV-specific CD8 ϩ T-cell responses in 2 D Ϫ /R ϩ pairs, 02 and 06. In recipient 02, an EBNA3C 880-891 -specific CD8 ϩ T-cell clone was obtained in the female recipient at 5 months following alloSCT from a male donor (clone 2.3), and this clone contained male DNA. We were unable to detect clonotype within donor PBMCs, or within PBMC samples taken from the recipient prior to transplantation or at 2 months following alloSCT. However, clonotype was detected in recipient PBMCs at 5, 9, and 18 months ( Figure 1B ), indicating that a primary EBV-specific CD8 ϩ T-cell response had occurred between 2 and 5 months after alloSCT, from cells of donor origin. In this recipient, because of renal insufficiency, cyclosporin was stopped at 3 months. In recipient 06, an EBV EBNA3C 281-290 -specific CD8 ϩ T-cell clone that contained donor DNA (clone 6.2) was obtained in this recipient at 6 years following alloSCT. We were unable to detect this clonotype within donor PBMCs, but clonotype was present in the recipient PBMC sample taken at 6 years following alloSCT (Table 4) . (A) Clonotypic probing was used to quantify the donor CD8 ϩ T-cell clone specific for HCMV pp65417-426 (clone 2.1) in sequential peripheral blood samples taken from recipient 02 before and after alloSCT. The clone was not detected in recipient 02 prior to transplantation but was detectable at all time points tested following alloSCT. All blood tests for HCMV DNAemia (performed weekly until 5 months after alloSCT) were negative. Because of renal dysfunction cyclosporin was discontinued at 3 months. (B) In the same EBV-seropositive recipient 02, an EBV EBNA3C880-891 CD8 ϩ T-cell clone (clone 2.3) was not present in the donor but following alloSCT was detected in the recipient from 5 months onward. With the use of clonotypic probing, the V␤14 ϩ donor CD8 ϩ T-cell clone specific for HCMV pp65417-426 (clone 7.1) was not detectable in any of the sequential peripheral blood samples taken from recipient 07 following alloSCT. Weekly blood tests for HCMV DNA were consistently negative. In the same donor-recipient pair, the V␤14 ϩ donor CD8 ϩ T-cell clone specific for EBV EBNA3C880-891 (clone 7.2) was detected in recipient PBMCs at all time points tested following alloSCT. In the controls, the HCMV ϩ -and EBV ϩ -labeled lanes refer to the positive control cDNA used from clones 7.1 and 7.2, respectively. (C) The V␤13.1 ϩ donor CD8 ϩ T-cell clone specific for HCMV pp65495-503 (clone 8.1) was detectable in sequential peripheral blood samples taken from recipient 08 after alloSCT. Recipient 08 had severe GVHD and died at 6 months after alloSCT. Weekly blood tests for HCMV DNA were negative.
following transplantation (having ceased ganciclovir prophylaxis at day ϩ100), accompanied by a strong anti-HCMV IgM response; the retinitis was successfully treated with ganciclovir. Ganciclovir prophylaxis was then re-instituted and continued until 10 months after alloSCT. An HCMV pp65 495-503 -specific CD8 ؉ T-cell clone obtained from recipient 05 at 21 months following alloSCT (clone 5.2; Table 4), contained donor DNA. We were unable to detect clonotype (or pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] peptide-specific CD8 ؉ T cells using tetramers) within donor PBMCs or within recipient PBMC samples taken prior to transplantation or at 3, 5, 7, and 9 months following alloSCT. Clonotype was detected at 12, 18, and 21 months, indicating that a primary CD8 ؉ T-cell response had occurred between 9 and 12 months after alloSCT in cells of donor origin, whereas the patient was receiving immunosuppressive therapy ( Figure 3) . An HCMV pp65495-503-specific CD8 ϩ T-cell clone (clone 5.2) was obtained from the HCMVseropositive recipient at 21 months after T-cell-depleted alloSCT. The clone was not detected in the donor or in recipient 05 prior to transplantation. Following an episode of HCMV retinitis at 5 months, the clone was first detected in recipient 05 at 12 months after alloSCT. The retinitis resolved following ganciclovir therapy, and subsequent weekly blood tests for HCMV DNA were negative. Following (D ϩ /R ϩ ) alloSCT in HCMV-seropositive recipients 01 and 04, we identified HCMV peptide-specific CD8 ϩ T-cell clones (clones 1.4 and 4.2, which both contained donor DNA) that were different from the HCMV peptide-specific CD8 ϩ T-cell clones obtained from their respective HCMV-seropositive donors (Table  4) . The IE72 198-207 -specific clonotype (clone 1.4) was first detected in PBMCs from recipient 01 at 5 months (while still receiving cyclosporin), and at all time points tested thereafter ( Figure 4A ). The delayed emergence of this T-cell clone in the recipient following alloSCT may be due to the generation of a novel CD8 ϩ T-cell clonotype that developed from donor-derived progenitor cells. Alternatively, this CD8 ϩ T-cell clone might represent delayed expansion of a subdominant clone already present in the donor at very low levels, below the levels of detection. To increase the sensitivity of clonotype detection, we used seminested PCR to amplify samples using V␤14-and C␤-specific primers, and then subsequent amplification using V␤14-and J␤1.1-specific primers. Repeated clonotype probing was again positive in the recipient PBMC sample taken at 5 months following alloSCT but was again negative for all other samples ( Figure 4B ). In recipient 04, a pp65 495-503 -specific CD8 ϩ T-cell clone (clone 4.2) was obtained 6 years following alloSCT. This clone was not detectable in donor PBMCs (Table 4 ). The clonotype frequency was similar at 6 years and 7 years, indicating that in fully reconstituted recipients, clones generated by late diversification are stably maintained over time.
Following alloSCT pp65 peptide-tetramer ؉ CD8 ؉ cells are abundant within the expanded CD28 ؊ CD8 ؉ , CD27 ؊ CD8 ؉ , and CD11b ؉ CD8 ؉ T-cell subpopulations but very rare in the CD28 ؉ CD45RA high population
Relative to their donors, in recipients 01 to 04 the CD28 Ϫ CD8 ϩ , CD27 Ϫ CD8 ϩ , and CD11b ϩ CD8 ϩ T-cell subpopulations were expanded ( Figure 5A ). This expansion was observed as early as 1 month and persisted long term. In recipients 01 to 04 (Ͼ 18 months after alloSCT) MHC class I HCMV pp65 495-503 and pp65 [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] tetramer ϩ CD8 ϩ T cells were predominant within the expanded CD28 Ϫ CD8 ϩ population (mean, 75% of all tetramer ϩ cells were CD28 Ϫ CD8 ϩ ; range, 59%-88%), within the expanded CD27 Ϫ CD8 ϩ population (70%; range, 43%-92%), and within the expanded CD11b ϩ CD8 ϩ population (80%; range, 67%-90%) ( Figure 5B ). For other CD8 ϩ T-cell subpopulations, the mean proportion of all tetramer ϩ cells was 19% (range, 9%-29%) in HLA-DR ϩ CD8 ϩ cells, 79% (range, 70%-88%) in CCR7 Ϫ CD8 ϩ cells, 45% (range, The CD8 ϩ T-cell clone generated in donor 01, which was specific for HCMV pp65495-503 (clone 1.1), was detectable in recipient 01 PBMCs at all time points tested following alloSCT. An HCMV IE72198-207-specific CD8 ϩ T-cell clone (clone 1.4) was obtained from recipient 01 at 13 months after alloSCT; this clone was not detected in the donor or in the recipient at 1 and 3 months after alloSCT but was first detected at 5 months following transplantation. In the controls, the pp65 ϩ -and IE72 ϩ -labeled lanes refer to the positive control cDNA used from clones 1.1 and 1.4, respectively. Weekly blood tests for HCMV DNA performed until cessation of immunosuppression at 15 months were negative. (B) PBMC samples in the same donor-recipient pair were amplified by seminested PCR as described. Clone 1.4 was not detectable in donor PBMCs or allograft, or in recipient samples taken prior to transplantation or at 1 and 3 months after alloSCT but was detected at 5 months. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From recipient minor histocompatibility antigens. 28 Recipient 08 was HLA-A2 positive and experienced severe acute GVHD, raising the possibility that this donor clone might be alloreactive and directly participating in the GVHD and/or that the inflammatory cytokines evoked by severe GVHD contributed to its maintenance. Interestingly, Cwynarski et al 10 reported that following HCMV D ϩ /R Ϫ alloSCT, pp65 tetramer ϩ CD8 ϩ T cells were detectable in only 1 of 7 recipients, and this recipient was the only one of the 7 recipients to experience acute GVHD.
The question of whether antigen-experienced T cells require exposure to antigen for their maintenance continues to be debated. Adoptive transfer experiments of antigen-experienced T cells into irradiated naive mice can result in long-term maintenance of antigen-specific T cells in the apparent absence of specific antigen. 29 Immune reconstitution following alloSCT in humans is likely to be more complex than in the mouse because adult humans are infected with a number of persistent viruses that undergo intermittent reactivation. Our data and those of Cwynarski et al 10 indicate that in human HCMV-seronegative alloSC transplant recipients, any transferred donor HCMV-specific CD8 ϩ T-cell clones may fail to compete successfully with other CD8 ϩ T cells (eg, EBV-specific CD8 ϩ T cells) that do encounter specific antigen in the recipient and proliferate strongly during reconstitution (as we consistently observed in EBV-seropositive recipients).
Human naive T cells can be generated within the first year after alloSCT. 8, 30 We found that seropositive recipients who received an alloSC transplant from a seronegative donor were able to generate a primary virus-specific CD8 ϩ T-cell response, from cells that contained donor DNA. These primary CD8 ϩ T-cell responses showed delayed kinetics and were not detectable prior to 5 months after alloSCT. Detection rates of both EBV DNA and HCMV DNA in serum are highest between 2 and 3 months after alloSCT, 31 and it may be that viral reactivation in vivo is necessary for induction of primary HCMV-specific or EBV-specific CD8 ϩ T-cell responses. The virus-specific CD8 ϩ T-cell clones that participated in the primary CD8 ϩ T-cell response may have been generated from mature naive T cells transferred from the donor within the graft or from newly generated naive T cells produced by de novo TCR gene recombination in the recipient from donor-derived progenitor cells. To address this issue, we analyzed HCMV-specific CD8 ϩ T-cell clones obtained from HCMV-seropositive recipient 05 following alemtuzumab-treated matched-unrelated donor transplantation from an HCMV-seronegative donor. Following an episode of HCMV disease, a primary HCMV-specific CD8 ϩ T-cell response developed in recipient 05 at 12 months after transplantation. In vivo alemtuzumab monoclonal antibody treatment results in a profound and sustained depletion of mature donor T cells transferred in the allograft. 32 The delayed emergence of the HCMV-specific T-cell clone in this recipient suggests that this clone was newly produced in the recipient by TCR gene recombination from donor progenitor cells, rather than mature naive donor T cells in the allograft.
In 2 of the 4 sibling pairs in which both donor and recipient were HCMV-seropositive, the CD8 ϩ T-cell clonal composition within the seropositive recipient became diversified in comparison with that of the seropositive donor, by the delayed emergence of additional CD8 ϩ T-cell clones that could not be detected prior to 5 months following transplantation. These additional T-cell clones contained donor DNA but could not be detected in either donor PBMCs or in recipient PBMCs during the first 5 months after transplantation. We have previously established that the probing assay is sufficiently sensitive to detect 1% specific clonotype sequence in a background of 99% different sequences that all have the same V␤ gene segment. 15 It is, therefore, likely that the delayed emergence of novel HCMV-specific T-cell clones was due to the generation of new T-cell clones in the recipient from progenitor cells of donor origin, rather than the delayed expansion of a subdominant clone present in donor PBMCs at very low levels.
Relative to the corresponding donor, among the total CD8 ϩ T-cell population in the recipient after alloSCT, the costimulatory molecules CD28 and CD27 are down-regulated, and the CD11b ϩ (a ␤ 2 integrin adhesion molecule) T-cell subpopulation is expanded. The increase in these subpopulations was observed early and persisted long term. In recipients analyzed more than 18 months following alloSCT, we found that most of the pp65 HCMV-specific CD8 ϩ T cells were in the expanded CD28 Ϫ and CD27 Ϫ populations and were CD11b ϩ and CCR7 Ϫ . Our findings are consistent with the results of Gamadia et al 33 who found that in patients receiving renal transplants, circulating HCMV-specific CD8 ϩ T cells were predominantly CD45R0 high CD27 Ϫ CCR7 Ϫ or CD45RA high CD27 Ϫ CCR7 Ϫ . These antigen-specific cells may use different forms of costimulation other than the CD28 or CD27 pathways, the precise nature of which remains to be determined. The CCR7 Ϫ and CD11b ϩ phenotype is consistent with the tissue-homing phenotype proposed by Sallusto et al. 34 In agreement with Cwynarski et al 10 we found the CD45RA expression of HCMV-specific CD8 ϩ T cells is heterogeneous, but as we found with healthy HCMV carriers, 35 the CD45RA high population of HCMV pp65-specific CD8 ϩ T cells within HCMV-seropositive recipients after alloSCT are almost entirely within CD28 Ϫ CD45RA high cells but were very rare in the CD28 ϩ CD45RA high population.
Thus, for both HCMV and EBV, donor virus-specific CD8 ϩ T-cell clones transferred within the graft can expand and persist within the recipient after sibling alloSCT when the recipient is seropositive, and in some but not all seropositive recipients after sibling alloSCT there is late diversification of the HCMVspecific CD8 ϩ T-cell clonal repertoire in response to persistent viral antigen.
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